AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37129197
Drug: Selinexor in
RxNorm normalized name: Product containing selinexor in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor in combination with pembrolizumab
Trial: 37129455
Drug: LCL161 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCL161 plus oral topotecan
Trial: 37129584
Drug: Ropeginterferon α-2b,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropeginterferon α-2b, starting dose of 250 μg, increasing to 350 μg at week 2 and 500 μg at week 4, with adjustments based on tolerability.
Trial: 37130017
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for up to 35 cycles (∼2 years)
Trial: 37130111
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) therapy for moderate-to-severe SRBDs
Trial: 37130158
Drug: Control (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (continued systemic chemotherapy)
Trial: 37130329
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive surgery for gastrointestinal cancer treatment
Trial: 37130668
Drug: Usual care,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care, plus weekly text messages to encourage walking and paper handouts
Trial: 37130681
Drug: T2DM remission
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T2DM remission defined as glycated haemoglobin (HbA1c) <6.0% without medications
Trial: 37130685
Drug: Rapid serological
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid serological test (RST) for SARS-CoV-2 antibodies (OrientGene)
Trial: 37131014
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + AC-T
Trial: 37131154
Drug: Standard immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immunotherapy (IO) regimen administered every 3 months
Trial: 37131154
Drug: Reduced intensity
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced intensity dose of IO administered every 3 months
Trial: 37131191
Drug: Bupivacaine dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine dose adjusted by height-based dosing algorithm
Trial: 37131191
Drug: Constant bupivacaine
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant bupivacaine dose
Trial: 37131265
Drug: Benralizumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab (30 mg subcutaneous doses at 4-week intervals)
Trial: 37131531
Drug: Intradermal acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal acupuncture (IDA)
Trial: 37131659
Drug: COVID-19 convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 convalescent plasma (CCP) with high antibody levels transfused early (symptom onset within 5 days)
Trial: 37131659
Drug: COVID-19 convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 convalescent plasma (CCP) with low antibody levels or control plasma
Trial: 37131755
Drug: Motivational Interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing (MI) intervention focusing on PrEP use and concomitant stimulant use or condomless anal sex
Trial: 37831485
Drug: Contingency Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency Management (CM) intervention with financial incentives for documented evidence of PrEP clinical evaluation and filling a PrEP prescription
Trial: 37131861
Drug: PHH-1V booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHH-1V booster vaccine
Trial: 37131861
Drug: BNT162b2 booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 booster vaccine
Trial: 37132281
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy with gemcitabine 1000 mg/m² and nab-paclitaxel
Trial: 37133249
Drug: Historical standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical standard of care (chemotherapy)
Trial: 37133584
Drug: Temporary interruption
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary interruption of adjuvant endocrine therapy to attempt pregnancy
Trial: 37133585
Drug: FTD-TPI plus
RxNorm normalized name: TPI-287
DrugBank: TPI-287 (DB17168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTD-TPI plus bevacizumab (combination group)
Trial: 37133647
Drug: Guideline-recommended medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guideline-recommended medications (ACE inhibitors)
Trial: 37133647
Drug: Guideline-recommended medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guideline-recommended medications (Angiotensin receptor blockers)
Trial: 37133647
Drug: Guideline-recommended medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guideline-recommended medications (Mineralocorticoid receptor antagonists)
Trial: 37133673
Drug: High-dose dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dual therapy (HDDT): rabeprazole 20 mg and amoxicillin 750 mg q.i.d for 14 days (n=122)
Trial: 37133673
Drug: Rabeprazole-containing hybrid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole-containing hybrid therapy (HT): rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days (n=121)
Trial: 37133829
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (systolic BP target < 120 mm Hg)
Trial: 37133829
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (systolic BP target < 140 mm Hg)
Trial: 37134108
Drug: Avasimibe (ACAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avasimibe (ACAT inhibitor)
Trial: 37134130
Drug: Fixed-schedule rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed-schedule rituximab infusion (500 mg)
Trial: 37134130
Drug: Tailored-infusion regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored-infusion regimen of rituximab
Trial: 37134130
Drug: Low rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Low rituximab plasma concentration at 3 months (CM3 <4 μg/ml)
Trial: 37134230
Drug: Conventional compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional compression dressing therapy
Trial: 37137304
Drug: ChemoID assay-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChemoID assay-guided chemotherapy
Trial: 37137304
Drug: Physician-chosen chemotherapy
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician-chosen chemotherapy
Trial: 37137527
Drug: Once-weekly subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly subcutaneous semaglutide
Trial: 37137553
Drug: BCMA CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCMA CAR-T therapy
Trial: 37137617
Drug: RBC folate
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RBC folate deficiency (<305 nmol/L) and insufficiency (<748 nmol/L)
Trial: 37138460
Drug: ChAdOx1 nCoV-19
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 vaccine trial participation
Trial: 37138473
Drug: Pegloticase (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegloticase (8 mg intravenous every 2 weeks)
Trial: 37138742
Drug: New Echinacea
RxNorm normalized name: Echinacea
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Echinacea formulation
Trial: 37138742
Drug: Conventional Echinacea
RxNorm normalized name: Echinacea
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Echinacea formulation
Trial: 37139775
Drug: Modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint-induced movement therapy (80 hours) and bimanual intensive therapy (20 hours)
Trial: 37139775
Drug: Bimanual intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bimanual intensive therapy (80 hours) and modified constraint-induced movement therapy (20 hours)
Trial: 37139775
Drug: Modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint-induced movement therapy (20 hours)
Trial: 37139775
Drug: Modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint-induced movement therapy (80 hours)
Trial: 37139775
Drug: Bimanual intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bimanual intensive therapy (20 hours)
Trial: 37140460
Drug: e-CBT and
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: e-CBT and treatment as usual (TAU)
Trial: 37140493
Drug: Buprenorphine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine administration initiated by practitioners
Trial: 37140493
Drug: 30-day treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30-day treatment engagement
Trial: 37140493
Drug: Attendance at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attendance at treatment visits
Trial: 37140517
Drug: 1:10,000-diluted topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:10,000-diluted topical epinephrine
Trial: 37140558
Drug: HilleVax bivalent
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 15/15 μg of GI.1/GII.4c genotype VLPs
Trial: 37140558
Drug: HilleVax bivalent
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 15/50 μg of GI.1/GII.4c genotype VLPs
Trial: 37140558
Drug: HilleVax bivalent
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 50/50 μg of GI.1/GII.4c genotype VLPs
Trial: 37140558
Drug: HilleVax bivalent
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 50/150 μg of GI.1/GII.4c genotype VLPs
Trial: 37140602
Drug: BI 836880
RxNorm normalized name: BI-836880
DrugBank: BI-836880 (DB17484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 836880 monotherapy (720 mg Q3W)
Trial: 37140602
Drug: BI 836880
RxNorm normalized name: BI-836880
DrugBank: BI-836880 (DB17484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 836880 (720 mg Q3W) plus ezabenlimab (240 mg Q3W)
Trial: 37140705
Drug: Vedolizumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab (3 doses during induction phase)
Trial: 37140727
Drug: Cotadutide (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotadutide (single dose)
Trial: 37140904
Drug: Bacterial decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial decolonization (BD) using intranasal mupirocin ointment twice daily and chlorhexidine body cleanser once daily for 5 days prior to RT and repeated for 5 days every 2 weeks through RT.
Trial: 37141260
Drug: Home-based inspiratory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based inspiratory muscle training (IMT) using 30% of maximal inspiratory pressure, increasing by 10% weekly, 30 repetitions, twice a day for 6 weeks.
Trial: 37141544
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus platinum-doublet chemotherapy
Trial: 37141544
Drug: Platinum-doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-doublet chemotherapy alone
Trial: 37141764
Drug: GLYT1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GLYT1 inhibitor (PF-03463275) 40 or 60 mg twice daily with cognitive training (CT)
Trial: 37141828
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for ≤35 cycles
Trial: 37141847
Drug: Avelumab 800
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 800 mg every 2 weeks (Q2W) and axitinib 5 mg orally two times daily
Trial: 37142308
Drug: Psilocybin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (15 mg)
Trial: 37142308
Drug: Psilocybin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (15 mg and 25 mg) with psychotherapy
Trial: 37142335
Drug: Maternal lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal lipid-based nutrient supplement initiated preconceptionally (arm 1, n=217)
Trial: 37142335
Drug: Maternal lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal lipid-based nutrient supplement initiated at 12 weeks gestation (arm 2, n=230)
Trial: 37142372
Drug: Tucatinib monotherapy
RxNorm normalized name: tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tucatinib monotherapy (cohort C)
Trial: 37142474
Drug: Average daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average daily opioid dose in morphine milligram equivalents (MME)
Trial: 37142543
Drug: Hematopoietic stem
RxNorm normalized name: Umbilical Cord Blood Hematopoietic Stem Cells
DrugBank: Umbilical Cord Blood Hematopoietic Stem Cells (DB15723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematopoietic stem cell transplantation (standard treatment)
Trial: 37142543
Drug: Gene addition
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene addition therapy
Trial: 37142730
Drug: Gemcitabine-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine-based treatment (n=99)
Trial: 37142733
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose antibiotic (IIIrd gen cephalosporin) administered within 30-min of POEM
Trial: 37142733
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose antibiotic (IIIrd gen cephalosporin) administered for a total of three days
Trial: 37142733
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose antibiotic (IIIrd gen cephalosporin)
Trial: 37142733
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose antibiotic (IIIrd gen cephalosporin)
Trial: 37143003
Drug: Blended Forensic
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended Forensic Outpatient Systemic Therapy (FASTb)
Trial: 37143003
Drug: Regular Forensic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular Forensic Outpatient Systemic Therapy (FASTr)
Trial: 37143128
Drug: Single application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single application of selective serotonin reuptake inhibitor (SSRI) or serotonin-noradrenaline reuptake inhibitor (SNRI)
Trial: 37143128
Drug: SSRI/SNRI combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI/SNRI combined with quetiapine (≥ 150 mg/day)
Trial: 37143154
Drug: MR-guided online
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-guided online adaptive radiotherapy (RT) with concurrent chemotherapy, conventionally fractioned RT with isotoxic dose escalation up to 70 Gy, online plan adaptation performed once weekly or in case of major anatomical changes.
Trial: 37143154
Drug: MR-guided online
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-guided online adaptive radiotherapy (RT) with concurrent chemotherapy.
Trial: 37143158
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (surgery followed by conventional radiotherapy after 1-2 weeks)
Trial: 37143685
Drug: Ruxolitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib plus simvastatin (5 mg BID for 7 days followed by 10 mg BID for 7 days and 40 mg once a day for 14 days)
Trial: 37143998
Drug: PACAP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PACAP infusion for 20 min
Trial: 37143998
Drug: VIP infusion
RxNorm normalized name: VIP
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIP infusion for 20 min
Trial: 37143999
Drug: Intra-arterial TNK
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial TNK (4 mg) followed by TNK (0.4 mg/min for 20 min) during EVT
Trial: 37144634
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.14 g·kg -1 ·d -1)
Trial: 37144820
Drug: CushMed (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CushMed (16 patients treated with stable cortisol-lowering drug dosage)
Trial: 37145134
Drug: Nd:YAG/Er:YAG dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG/Er:YAG dual laser therapy (4 treatments, 1-2 months apart)
Trial: 37145134
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid application (6 months)
Trial: 37145134
Drug: Nd:YAG/Er:YAG dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG/Er:YAG dual laser therapy
Trial: 37145134
Drug: Nd:YAG/Er:YAG dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG/Er:YAG dual laser therapy and Topical steroid application
Trial: 37145169
Drug: ONC201 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 and paxalisib (combination)
Trial: 37145975
Drug: Zanubrutinib co-administered
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib co-administered with rifabutin
Trial: 37146180
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake of 235 (133, 401) μg/day
Trial: 37146180
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake >400 μg/day
Trial: 37146180
Drug: Long-term iodine
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term iodine intake >400 μg/day
Trial: 37146444
Drug: StayWell text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: StayWell text messaging intervention (60-day program based on cognitive behavioral therapy)
Trial: 37146752
Drug: Durvalumab 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 20 mg/kg plus tremelimumab 1 mg/kg administered intravenously every 4 weeks for four doses, followed by up to nine doses of durvalumab monotherapy every 4 weeks for up to 12 months or until disease progression
Trial: 37146874
Drug: Acceptance-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-based behavioral therapy (ABBT) plus treatment-as-usual (TAU)
Trial: 37147083
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza vaccine (LAIV) administration
Trial: 37147201
Drug: 3-antigen vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-antigen vaccine (PreHevbrio™)
Trial: 37147201
Drug: Single-antigen vaccine
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-antigen vaccine (Engerix-B)